Salute e Benessere

Sanner Group acquires Gilero to expand its global medical device offering

Sanner Group acquires Gilero to expand its global medical device offering Acquisition drives Sanner Group's mission to offer a suite of world leading development and manufacturing services for its customers across the drug delivery and medical device sectors25 September 2024 - Sanner Group (“Sanner”), a leading global healthcare packaging and medical device CDMO has acquired Gilero LLC (“Gilero”), a world class medical device design, development, and contract manufacturer headquartered...
Nasdaq GlobeNewswire
25/09/2024

Rx-360 Announces Approval as a Pilot Center of Excellence for the APEC…

Economies are adversely impacted by the international movement of substandard and falsified medical products. As the medical products industry has become more globalized and specialized, APEC economies are faced with many challenges in keeping citizens healthy, while ensuring that access to legitimate products is not disrupted. To address this issue, the Roadmap for Global Medical Product Quality and Supply Chain Security project (Roadmap) was developed. The Roadmap was a multi-year effort…
PR Newswire
25/09/2024

Coloplast A/S - Financial Calendar 2024-25

Please see enclosed pdf.For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 For further information, please contactInvestors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458...
Nasdaq GlobeNewswire
25/09/2024

SI GROUP ANNOUNCES PLANS TO CLOSE MANUFACTURING SITE IN SINGAPORE

SI Group opened its alkylphenol manufacturing plant on Jurong Island in 2006 to provide alkylphenols to Asia Pacific consumers and for production of SI Group antioxidant products. Yet, due to the substantial changes in the antioxidant value chain in the region in recent years, paired with high costs in Singapore, the company will cease production there next year. "SI Group's manufacturing facility in Singapore has been a valuable asset for our past growth and global presence," said…
PR Newswire
25/09/2024

Vanderbilt University School of Medicine Basic Sciences Adds Carterra's LSAXT…

"Many of our researchers are trying to identify antibodies that bind to a protein involved in health or disease," said Borden Lacy, director of the CSB and Edward and Nancy Fody Chair in Pathology and professor of biochemistry and pathology, microbiology and immunology. "The ability to rapidly screen and quantify binding for large libraries of antibodies will shape the way molecular discovery moves forward at Vanderbilt. The work we spend months on will now be completed in a…
PR Newswire
25/09/2024

OrbusNeich Launches a High-Capacity Logistics Center in the Netherlands

Commenting on the logistics center opening, Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich stated, "This investment aligns perfectly with our strategic vision as it enhances and strengthens our integrated supply chain. Following our recent acquisition of eucatech AG, we have enriched our product portfolio with innovative devices such as drug-eluting balloons. This expansion reinforces our commitment to providing superior quality products to customers…
PR Newswire
25/09/2024

Sanofi: Poland's EU Presidency - Paving the Way for a Competitive Pharmaceutical…

Digital Transformation of Healthcare Digital Transformation of Healthcare Another major health priority duringPoland'sPresidency will be the digital transformation of healthcare, focusing on cybersecurity for medical devices and the implementation of the European Health Data Space (EHDS). The exchange of cross-border digital health data will be a central theme, with a conference planned for May to explore patients' roles in this evolving landscape. Health Prevention Initiatives and...
PR Newswire
25/09/2024

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar…

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio®Sales of Entyvio (vedolizumab) were about $5.4 billion globally in the last 12 months up to June 30, 2024 Entyvio is indicated for the treatment of Ulcerative Colitis and Crohn's diseaseAlvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Nasdaq GlobeNewswire
25/09/2024

Gedeon Richter presents analysis on cannabis usage among patients with…

Schizophrenia often co-occurs with cannabis use disorder however, available antipsychotic treatments frequently fail to address both disorders. In a scientific poster showcased by Gedeon Richter at ECNP in Milan, cariprazine was presented to be a potentially effective treatment option for patients with first-episode schizophrenia and comorbid cannabis use disorder according to the results of a 6-month observational study. Four other scientific posters were also presented at the congress by…
PR Newswire
25/09/2024

Synergy Spine Solutions announces completion of patient enrollment in the…

Conducted under a U.S. Investigational Device Exemption (IDE), the 2-Level trial will evaluate the safety and effectiveness of the Synergy Disc® artificial cervical disc, compared to anterior cervical discectomy and fusion (ACDF), for the treatment of degenerative disc disease in subjects that are symptomatic at two contiguous levels from C3 to C7. The Synergy Disc trial is a multi-center, prospective, non-randomized, historically controlled study that is being conducted on 200 patients...
PR Newswire
25/09/2024

FONDAZIONE PRADA PRESENTS "PRESERVING THE BRAIN: A CALL TO ACTION" IN MILAN

"Human Brains" is the result of an in-depth research process undertaken by Fondazione Prada and driven by a deep interest in understanding the human brain, the complexity of its functions and its centrality in human history. Developed by a scientific committee chaired by neurologist Giancarlo Comi, since 2020 the program resulted in a series of exhibitions, scientific conferences, public talks, and online and editorial activities. "Human Brains" is the result of an in-depth…
PR Newswire
25/09/2024

Implantica shares a landmark review article on standard of care Nissen…

The highest complication rates 5 years post-procedure are the side effects gas bloating (52.7%), inability to belch/vomit (39.8%), swallowing difficulties/dysphagia (28.9%) and heartburn, epigastric/sternal pain (27.0%). Combining medical PPI usage and re-operations can provide an estimation of a failure rate, and this amounted to 20.6% after 5 years. The highest complication rates 5 years post-procedure are the side effects gas bloating (52.7%), inability to belch/vomit (39.8%), swallowing...
PR Newswire
25/09/2024

Implantica announces finalization of remarkable 5-year pivotal CE mark study…

Module 2 is the most important of the three modules included in the PMA filing and will contain the clinical and usability data, including the results of the CE-mark clinical investigation and the results from our Human Factors Validation Study performed earlier this year with 16 US foregut/reflux surgeons in Chicago. Module 2 is the most important of the three modules included in the PMA filing and will contain the clinical and usability data, including the results of the CE-mark clinical...
PR Newswire
25/09/2024

Caristo Diagnostics Offers £500 to First 100 UK Patients Who Get Advanced Heart…

A May 29 study in the medical journal, The Lancet, examined CaRi-Heart analysis of 40,000 CCTA heart scans and confirmed that the technology can detect invisible coronary inflammation and determine an individual's long-term risk of a fatal cardiac event. CaRi-Heart's unique ability to see coronary inflammation is crucial for the significant number of patients with chest pain who receive a negative CCTA result but nevertheless remain at high risk for cardiovascular events. A May 29 study in…
PR Newswire
25/09/2024

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress…

Poster Title: Multiple switching between the biosimilar adalimumab-fkjp low concentration and reference adalimumab high concentration in patients with chronic plaque psoriasis: a phase 3, double-blind, randomised, parallel-group studyAuthors: Sarika Deodhar, Subramanian Loganathan, Ramesh Ks, Gopi Ranganna, Shiyao Liu, Matthew A. Hummel Hummel, Stefan Daniluk, Anna Hanczewska, Kamelia Vekovska, Maria Zegadlo-Mylik, Grazyna Pulka, Elena Wolff-HolzAbstract ID: 3809Poster ID: P3241Date/Time: 9:00am…
PR Newswire
25/09/2024

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its…

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatricin-vivogene therapy into the clinic One of the largest private Italian Biotech company financings to dateFinancing co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital forming a strong syndicate with Indaco SGR Funds dedicated to advancing off-the-shelf pediatric gene therapy for Methylmalonic Acidemia (MMA) into the clinic, and to bolstering the Company's...
Nasdaq GlobeNewswire
25/09/2024

Junshi Biosciences Announces European Commission Approval for Marketing of…

® ) for the treatment of two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC);Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC). In July, a positive opinion was issued...
Nasdaq GlobeNewswire
25/09/2024

G7 DFIs, MedAccess, EIB, and IFC Announce MoU for Surge Financing Initiative for…

The MoU was signed by the U.S. International Development Finance Corporation (DFC, USA), Cassa Depositi e Prestiti (CDP, Italy), British International Investment (BII) & MedAccess (UK), KfW & Germany's Development Finance Institution DEG (Germany), AFD & Proparco (France), JICA (Japan), EIB (European Union), and IFC (World Bank Group). The MoU also has support from the Government of Canada and leading global and regional health organizations. The MoU was signed by the U.S…
PR Newswire
25/09/2024

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common…

HS is currently estimated to affect approximately 1 in 100 people, with obesity being a significant risk factor. The condition is characterised by painful abscesses and scarring, which can severely impact patients' quality of life. Despite advancements in managing HS, effective treatments remain limited and can cause serious side effects, highlighting a need for alternative and better-tolerated treatment options. HS is currently estimated to affect approximately 1 in 100 people, with obesity...
PR Newswire
25/09/2024

Global Cell Therapy Biomanufacturing Market Projected to Reach $16.7 Billion by…

The global cell therapy biomanufacturing market is currently experiencing dynamic shifts driven by significant R&D investments, intensified competition among industry players, and the rapid emergence of innovative technologies. These factors are pivotal in shaping market growth trajectories while offering valuable insights for stakeholders and potential entrants alike. The landscape is further influenced by ongoing advancements and frequent product launches, bolstered by supportive…
PR Newswire
24/09/2024

Genomics Market to Reach $70.52 Billion by 2031, Driven by Increasing…

Download FREE PDF Brochure Of Genomics Market –https://www.meticulousresearch.com/download-sample-report/cp_id=1262 Download FREE PDF Brochure Of Genomics Market–https://www.meticulousresearch.com/download-sample-report/cp_id=1262 The rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, growing applications of genomics in the healthcare sector, rising pharmaceutical R&D...
PR Newswire
24/09/2024

CARBIOS and Selenis announce strategic partnership to produce PETG issued from…

Clermont-Ferrand (France), Tuesday 24 September 2024 (6pm CEST).-CARBIOS ,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andSELENIS, a leading supplier of high-quality specialty polyester solutions, have signed a Letter of Intent (LOI) to cooperate in the production of PETG 1. By leveraging CARBIOS' unique enzymatic depolymerization technology and Selenis' expertise...
Nasdaq GlobeNewswire
24/09/2024

Eurobio Scientific: RESULTS FOR THE 1ST HALF OF 2024

RESULTS FOR THE 1 STHALF OF 2024 Revenues up 12% on a like-for-like basis (24% overall)Stable adjusted EBITDA 1and operating profitNet financial debt down slightly to €1.6m, with cash of €86.6mProposed voluntary takeover bid Paris, September 24, 2024 - 6pm - Eurobio Scientific(FR0013240934, ALERS), a leading French group inin vitromedical diagnostics and life sciences, today announced its consolidated annual results at June 30, 2024, prepared under French...
Nasdaq GlobeNewswire
24/09/2024

Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production…

Contract will further strengthen the U.S, bulk vaccine inventory and secure additional freeze-dried dosesDeliveries planned for 2025 and beyondCOPENHAGEN, Denmark, September 24, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and...
Nasdaq GlobeNewswire
24/09/2024
Altri  Comunicati